주식/증권
➡️ 중립
Biogen Moves Alzheimer’s Drug to Late-Stage Trials. Wall Street Thinks It’s a Mistake.
요약
Biogen’s diranersen showed ‘robust reductions’ in key biomarkers during a Phase 2 trial, the biotech said.